535 related articles for article (PubMed ID: 18657182)
21. Effects of URB597 as an inhibitor of fatty acid amide hydrolase on modulation of nociception in a rat model of cholestasis.
Hasanein P; Shahidi S; Komaki A; Mirazi N
Eur J Pharmacol; 2008 Sep; 591(1-3):132-5. PubMed ID: 18593578
[TBL] [Abstract][Full Text] [Related]
22. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease.
Bisogno T; Martire A; Petrosino S; Popoli P; Di Marzo V
Neurochem Int; 2008 Jan; 52(1-2):307-13. PubMed ID: 17664017
[TBL] [Abstract][Full Text] [Related]
23. The endocannabinoid-CB(1) receptor system in pre- and postnatal life.
Fride E
Eur J Pharmacol; 2004 Oct; 500(1-3):289-97. PubMed ID: 15464041
[TBL] [Abstract][Full Text] [Related]
24. Beneficial effects of cannabinoids (CB) in a murine model of allergen-induced airway inflammation: role of CB1/CB2 receptors.
Braun A; Engel T; Aguilar-Pimentel JA; Zimmer A; Jakob T; Behrendt H; Mempel M
Immunobiology; 2011 Apr; 216(4):466-76. PubMed ID: 21056512
[TBL] [Abstract][Full Text] [Related]
25. The expression of receptors for endocannabinoids in human and rodent skeletal muscle.
Cavuoto P; McAinch AJ; Hatzinikolas G; Janovská A; Game P; Wittert GA
Biochem Biophys Res Commun; 2007 Dec; 364(1):105-10. PubMed ID: 17935697
[TBL] [Abstract][Full Text] [Related]
26. Role of lipids and lipid signaling in the development of cannabinoid tolerance.
Martin BR
Life Sci; 2005 Aug; 77(14):1543-58. PubMed ID: 15949820
[TBL] [Abstract][Full Text] [Related]
27. Endocannabinoids in the immune system and cancer.
Parolaro D; Massi P; Rubino T; Monti E
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):319-32. PubMed ID: 12052046
[TBL] [Abstract][Full Text] [Related]
28. Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis.
Pryce G; Baker D
Handb Exp Pharmacol; 2015; 231():213-31. PubMed ID: 26408162
[TBL] [Abstract][Full Text] [Related]
29. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
[TBL] [Abstract][Full Text] [Related]
30. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review.
Svízenská I; Dubový P; Sulcová A
Pharmacol Biochem Behav; 2008 Oct; 90(4):501-11. PubMed ID: 18584858
[TBL] [Abstract][Full Text] [Related]
31. Cannabinoid receptors in conjunctival epithelium: identification and functional properties.
Iribarne M; Torbidoni V; Julián K; Prestifilippo JP; Sinha D; Rettori V; Berra A; Suburo AM
Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4535-44. PubMed ID: 18566465
[TBL] [Abstract][Full Text] [Related]
32. Latest advances in cannabinoid receptor agonists.
Thakur GA; Tichkule R; Bajaj S; Makriyannis A
Expert Opin Ther Pat; 2009 Dec; 19(12):1647-73. PubMed ID: 19939187
[TBL] [Abstract][Full Text] [Related]
33. Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats.
; De Filippis D; D'Amico A; Cipriano M; Petrosino S; Orlando P; Di Marzo V; Iuvone T
Pharmacol Res; 2010 Apr; 61(4):321-8. PubMed ID: 19931394
[TBL] [Abstract][Full Text] [Related]
34. Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent.
Borrelli F; Romano B; Petrosino S; Pagano E; Capasso R; Coppola D; Battista G; Orlando P; Di Marzo V; Izzo AA
Br J Pharmacol; 2015 Jan; 172(1):142-58. PubMed ID: 25205418
[TBL] [Abstract][Full Text] [Related]
35. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals.
Re G; Barbero R; Miolo A; Di Marzo V
Vet J; 2007 Jan; 173(1):21-30. PubMed ID: 16324856
[TBL] [Abstract][Full Text] [Related]
36. Alterations in the endocannabinoid system in the rat valproic acid model of autism.
Kerr DM; Downey L; Conboy M; Finn DP; Roche M
Behav Brain Res; 2013 Jul; 249():124-32. PubMed ID: 23643692
[TBL] [Abstract][Full Text] [Related]
37. The antinociceptive effects of local injections of propofol in rats are mediated in part by cannabinoid CB1 and CB2 receptors.
Guindon J; LoVerme J; Piomelli D; Beaulieu P
Anesth Analg; 2007 Jun; 104(6):1563-9, table of contents. PubMed ID: 17513659
[TBL] [Abstract][Full Text] [Related]
38. Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?
Wilkerson JL; Bilbrey JA; Felix JS; Makriyannis A; McMahon LR
Pharmacol Biochem Behav; 2021 Jul; 206():173192. PubMed ID: 33932409
[TBL] [Abstract][Full Text] [Related]
39. Endocannabinoid System Contributes to Liver Injury and Inflammation by Activation of Bone Marrow-Derived Monocytes/Macrophages in a CB1-Dependent Manner.
Mai P; Yang L; Tian L; Wang L; Jia S; Zhang Y; Liu X; Yang L; Li L
J Immunol; 2015 Oct; 195(7):3390-401. PubMed ID: 26320250
[TBL] [Abstract][Full Text] [Related]
40. Cannabinoids in the treatment of pain and spasticity in multiple sclerosis.
Smith PF
Curr Opin Investig Drugs; 2002 Jun; 3(6):859-64. PubMed ID: 12137404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
